{"id":2621,"date":"2018-04-18T22:17:21","date_gmt":"2018-04-18T16:47:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2621"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"notizia-latest-pharam-news","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news","title":{"rendered":"Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Positive Phase 1 data supports Cyclacel\u2019s plans for CDK2\/9 inhibitor CYC065<\/strong><\/p>\n<p style=\"text-align: justify;\">Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CDK drug has shown that it can successfully stabilize disease in advanced cancers. After positive results now the drug will further be taken into a trial in combination with AbbVie\u2019s expected to be leukemia blockbuster Venclexta.<\/p>\n<p style=\"text-align: justify;\"><strong>Lysogene delays phase 3 study of Sanfilippo gene therapy <\/strong><\/p>\n<p style=\"text-align: justify;\">Lysogene\u2019s pivotal Sanfilippo syndrome trial is\u00a0pushed back by a manufacturing delay. Lysogene has been working on CMC topic for quite some time but is yet to get its manufacturing setup to the point where it can possibly support the phase 2\/3 trial. Due to the unavailability of a working manufacturing plant the start date for the trial has shifted to latter half of 2018.<\/p>\n<p style=\"text-align: justify;\"><strong>Diagnosis of genetic disorders could further be improved by Genotype-first approach <\/strong><\/p>\n<p style=\"text-align: justify;\">Group of scientists from around the world had started with a genetic mutation and\u00a0further tracked down\u00a0the people who were suffering from it. in the process 37 individuals with an NAA15 mutation and a multitude of symptoms were discovered. Genotype-first&#8221; method could fine-tune the existing diagnostic process and help researchers devise treatments for genetic disease, saving a lot of time and improving the treatment method.<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 resistance in melanoma patients successfully reversed by checkmate\u2019s I-O combo<\/strong><\/p>\n<p style=\"text-align: justify;\">Checkmate Pharmaceuticals has recently unveiled the phase 1 data of its lead asset, CMP-001, in combination with Merck\u2019s Keytruda at AACR, the combination has successfully reversed PD-1 resistance in advanced melanoma patients who had failed a prior anti-PD-1 treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Positive Phase 1 data supports Cyclacel\u2019s plans for CDK2\/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CDK drug has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,1118,1602,1596,204,1600,349,1599,1601,1230,639,1196,1267,706,1598,1597],"industry":[17225],"therapeutic_areas":[17235,17238,17228],"class_list":["post-2621","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-business-research","tag-checkmate","tag-cyclacel","tag-delveinsight","tag-genotype-first-approach","tag-latest-pharma-news","tag-lysogene","tag-naa15-mutation","tag-pharma-consultancy","tag-pharma-news","tag-pharma-research","tag-pharmaceutical-consultancy","tag-pharmaceutical-industry","tag-sanfilippo-gene-therapy","tag-venclexta","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Phase 1 data of CYC065; Lysogene delays phase 3 study<\/title>\n<meta name=\"description\" content=\"Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 1 data of CYC065; Lysogene delays phase 3 study\" \/>\n<meta property=\"og:description\" content=\"Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-18T16:47:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Phase 1 data of CYC065; Lysogene delays phase 3 study","description":"Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news","og_locale":"en_US","og_type":"article","og_title":"Phase 1 data of CYC065; Lysogene delays phase 3 study","og_description":"Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares.","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-04-18T16:47:21+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news","name":"Phase 1 data of CYC065; Lysogene delays phase 3 study","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-04-18T16:47:21+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharam-news#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">checkmate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cyclacel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genotype-first approach<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lysogene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NAA15 mutation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanfilippo gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Venclexta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">checkmate<\/span>","<span class=\"advgb-post-tax-term\">Cyclacel<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Genotype-first approach<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lysogene<\/span>","<span class=\"advgb-post-tax-term\">NAA15 mutation<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical consultancy<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Sanfilippo gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Venclexta<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 18, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 18, 2018 10:17 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2621"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2621\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2621"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2621"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}